IR in acute cystitis group did not show significant difference when compared with group A (p>0.05). In chronic cystitis group, p-CREB-IR in the L1-L6 and S1 DRG was significantly greater than control (p<0.05), and p-CREB-IR in the L3-L6 and S1 DRG was significantly greater than that in acute cystitis group (p<0.05). In control and acute cystitis group, p-CREB-IR in the L4-L5 DRG was significantly smaller than the other DRGs (p<0.05). p-CREB-IR in the L6 and S1 DRG was significantly greater than L4-L5 DRG among chronic cystitis group (p<0.05).
INTRODUCTION AND OBJECTIVES: Urinary tract infection
(UTI) is more common and has worse outcomes in people with diabetes mellitus (DM). The mechanisms that predispose diabetics to UTI are not defined. Uropathogens are rapidly developing antibiotic resistance. Thus, a greater understanding of host defenses that protect the urinary tract from microbial insult are needed to develop new UTI treatment options that will improve care provided to people with DM. This project was designed to investigate how insulin signaling affects urothelial antibacterial defenses and UTI susceptibility, independent of hyperglycemia and glucosuria.
METHODS: To investigate the impact of insulin signaling on bladder innate defenses, we genetically deleted the insulin receptor (IR) in the urothelium. Urothelial-specific IR knock-out mice (IRKO) were generated by breeding homozygous mice for the floxed Insr gene with mice that express a tamoxifen-inducible Cre recombinase under the Uroplakin 2 (Upk2) promoter. Littermates lacking the Upk2-Cre transgene served as controls (IRflox). To determine if urothelialspecific IR deletion impacts host defense, female mice were transurethrally infected with uropathogenic E. coli (UPEC). UPEC burden was enumerated in urine, bladder, and kidney post infection. To assess how IR deletion increases UTI risk, antibacterial peptide (AMP) expression and urothelial barrier formation were assessed.
RESULTS: Compared to controls, IRKO mice exhibit normal development, normal bladder histology, and no evidence of hyperglycemia/glucosuria. IRKO mice were more susceptible to experimental UTI compared to controls, as significantly greater UPEC titers were enumerated in their urine, bladder, and kidneys. This was accompanied by increased bladder edema and inflammatory scores. IR deletion suppressed urothelial AMP mRNA expression and increased urothelial permeability in vivo. To confirm that suppressed AMP expression increases UPEC susceptibility, AMPs were silenced in 5637 urothelial cells in vitro. siRNA-mediated AMP silencing increased UPEC cellular invasion. Similarly, siRNA-mediated INSR knock-down decreased urothelial barrier formation and increased urothelial permeability.
CONCLUSIONS: These results suggest that defective insulin signaling impairs urothelial innate defenses. Also, they indicate that hyperglycemia alone does not explain increased UTI risk. In part, increased UPEC susceptibility may be due to decreased expression of AMPs or disrupted urothelial barrier formation, indicating potential targets for mitigating UTI risk in insulin-resistant individuals.
Source of Funding: National Institutes of Health (NIDDK R01 DK114035).
MP71-07 HIPPO/YAP PATHWAY IN OBSTRUCTIVE UROPATHY: A NOVEL CONTRIBUTOR AND PROMISING THERAPEUTIC TARGET
Erin Salter*, Jiaqi Tang, Paul Higgins, Rohan Samarakoon, Albany, NY INTRODUCTION AND OBJECTIVES: Despite success of surgical intervention in relieving ureteral obstruction, a fraction of patients develop resultant renal fibrosis and end stage kidney disease. Hippo pathway is a major regulator of organ size, with Yes associated protein (YAP) and its paralog, Transcriptional coactivator with PDZ-binding motif (TAZ), as its major nuclear effectors. We recently demonstrated that TAZ upregulation consequent to obstructive renal injury contributes to progressive fibrosis. The mechanistic contribution of YAP, however, was not investigated. Here, we test the hypothesis that YAP renal induction in obstructive uropathy promotes fibrotic epithelial dysfunction and assess Verteporfin as a potential anti-fibrotic agent.
METHODS: We utilized a mouse model of unilateral ureteral obstruction (UUO) to investigate YAP involvement in obstructive nephropathy. Human kidney tubular epithelial cells (HK-2) were stably transduced with either control vector (CMV-Control) or YAP1 (CMV-YAP) expression contracts, driven by CMV promoter via lentiviral transduction. Phenotypic alterations, fibrotic marker expression and growth properties of these transgenic cells were assessed by microscopy, western blot analysis and flow cytometry. Pharmacologic inhibition of YAP/TAZ is also investigated as a therapeutically relevant anti-fibrotic approach.
RESULTS: YAP expression was elevated in tubulointerstitial regions of UUO kidneys compared to contralateral controls, correlating with fibrosis. HK-2 cells with stable YAP1 expression, mimicking epithelial YAP upregulation during kidney obstruction, underwent epithelial dedifferentiation, marked by loss of epithelial marker E-Cadherin and acquisition of mesenchymal properties including vimentin upregulation. CMV-Control HK-2 cells retained epithelial characteristics including cuboidal appearance and E-Cadherin expression. YAP overexpressing cells assumed fibrogenic properties, evident by increased fibronectin, Collagen-1 expression; underwent G2/M cell cycle arrest; and promoted p21 upregulation compared to control cells. Blockade of YAP/TAZ activation with a clinically relevant drug, verteporfin attenuated the fibrotic reprogramming induced by YAP upregulation.
CONCLUSIONS: YAP upregulation promotes epithelial plasticity and growth inhibition, contributing to dysfunctional renal epithelium and fibrotic maladaptive repair. Verteporfin could be a novel and plausible strategy to reduce prevalence of obstructive uropathy via pharmacologic and molecular targeting of YAP upregulation. METHODS: A retrospective review was performed of patients presenting to the emergency room from December 2017 to October 2018 with obstructing urolithiasis and clinical concern for infection evaluated for stent / nephrostomy tube decompression. A true UTI was defined as any of the following: gross purulence proximal to the stone or positive catheterized bladder, renal pelvic, or blood cultures. Over 30 demographic, symptom, comorbidity, laboratory, and radiographic parameters were tested on univariable analyses to determine association
